

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: August 8, 2005 (use as many sheets as necessary)		Complete if Known	
1 of 2		Application Number Filing Date First Named Inventor Group Art Unit Examiner Name	10/706,328 11/12/2003 Alison Hannah 1644 Attorney Docket Number
		072121-0366	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

NON PATENT LITERATURE DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>DL</i>		Zetter, B. R., "Angiogenesis and Tumor Metastasis," Annu. Rev. Med., 1998, Vol. 49, pp. 407-24; published by Annual Review Inc.
		MSNBC News Services, "Mixed results on new cancer drug," November 9, 2000.

Examiner Signature  Date Considered 12/10/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.** SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

B

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/706,328
Date Submitted: August 8, 2005 (use as many sheets as necessary)				Filing Date	11/12/2003
				First Named Inventor	Alison Hannah
				Group Art Unit	1644
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	072121-0366

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AP		Gura, T., "Systems for Identifying New Drugs Are Often Faulty," <i>Science</i> , 1997, Vol. 278, pp. 1041-1042.	
		Dermer, G. B., "Another Anniversary for the War on Cancer," <i>Biotechnology</i> , 1994, Vol. 12, p. 320.	
		Freshney, R. I., <i>Culture of Animal Cells – A Manual of Basic Technique</i> , 1983, pp. 1-4; published by Alan R. Liss, Inc.	
		Angiogenesis Foundation, "New Study Shows That Acute Myeloid Leukemia is Angiogenesis-Dependent," January 4, 2000; www.angio.org/newsandviews/archive2000/jan_4_2000.html .	
		Hussong, J. W. et al., "Evidence of increased angiogenesis in acute myeloid leukemia," <i>Blood</i> , 2000, Vol. 95(1), pp. 309-313; The American Society of Hematology.	
		Kerbel, R. S., "Tumor Angiogenesis: Past, Present and Near Future," <i>Carcinogenesis</i> , 2000, Vol. 21(3), pp. 505-515; Oxford University Press.	
		Lundberg, L. G. et al., "Bone Marrow in Polycythemia Vera, Chronic Myelocytic Leukemia, and Myelofibrosis Has an Increased Vascularity," <i>American Journal of Pathology</i> , 2000, Vol. 157(1), pp. 15-19.	
		Dankbar, B. et al., "Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma," <i>Blood</i> , 2000, Vol. 5(8), pp. 2630-2636.	
		Menzel, T. et al., "Elevated Intracellular Level of Basic Fibroblast Growth Factor Correlates with Stage of Chronic Lymphocytic Leukemia and is Associated With Resistance to Fludarabine," <i>Blood</i> , 1996, Vol. 87(3), pp. 1056-1063.	
		Gruber, G. et al., "Basic Fibroblast Growth Factor is Expressed in CD19/CD11c-Positive Cells in Hairy Cell Leukemia," <i>Blood</i> , 1999, Vol. 94(3), pp. 1077-1085.	


Examiner Signature		Date Considered	12/10/05
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Form PTO-1449 (MODIFIED)			U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 072121-0366	SERIAL NO. 10/706, 328	
INFORMATION DISCLOSURE CITATION Date Submitted: January 12, 2005 (Use several sheets if necessary)			APPLICANT Hannah et al.				
			FILING DATE 11/12/2003		GROUP ART UNIT 1644		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL <i>Al</i>	REF	DOCUMENT NUMBER 	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
<i>Al</i>	Salmon, S. E. et al., <i>Basic & Clinical Pharmacology</i> , Seventh Edition, edited by B. Katzung, Appleton & Lange, pp. 29, 881-884 (1998).						
	Milauer, B. et al., "Glioblastoma Growth Inhibited In Vivo by a Dominant-Negative Flk-1 Mutant," <i>Nature</i> , Vol. 367, pp. 576-579 (1994); published by Nature Publishing Group.						
	Pinedo, H. M. et al., "Translational Research: The Role of VEGF in Tumor Angiogenesis," <i>The Oncologist</i> 2000, Vol. 5 (suppl. 1), pp. 1-2 (2000).						
	McMahon, G., "VEGF Receptor Signaling in Tumor Angiogenesis," <i>The Oncologist</i> 2000, Vol. 5 (suppl. 1), pp. 3-10 (2000).						
EXAMINER <i>Al</i>	DATE CONSIDERED <i>12/10/05</i>						
<p>* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.</p>							



**Form PTO-1449
(MODIFIED)**

U. S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
072121-0366

SERIAL NO. 10/706,328

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

1/12/2003

13 200

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO
00	WO 2004/063151	7/29/04	PCT				
	WO 2004/030620	4/15/04	PCT				
	WO 2004/031401	4/15/04	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER


DATE CONSIDERED

2/10/05

- EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

三

- EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449 (MODIFIED 12-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 072121-0366	SERIAL NO. 10/706,328		
 INFORMATION DISCLOSURE CITATION DEC 22 2003 (Use several sheets if necessary)		APPLICANT		Vora et al.			
		FILING DATE		GROUP ART UNIT Unassigned			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							YES
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
QD		Carmeliet, P. et al. "Angiogenesis in Cancer and Other Diseases," Nature, 407, pp. 249-257 (2000).					
EXAMINER		 DATE CONSIDERED <i>12/10/05</i>					
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							



FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Date Submitted to PTO: December 10, 2003			DOCKET NO. 072121-0366	SERIAL NO. 10/706,328			
			APPLICANTS Jayesh VORA et al.				
			FILING DATE November 12, 2003		GROUP Unassigned		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>Al</i>	A1	5,073,492	Dec. 17, 1991	Chen et al.			
	A2	5,414,088	May 9, 1995	Von Der Saal et al.			
	A3	5,585,380	Dec. 17, 1996	Bianco et al.			
	A4	5,646,153	Jul. 8, 1997	Spada et al.			
	A5	5,710,158	Jan. 20, 1998	Myers et al.			
	A6	5,763,441	Jun. 9, 1998	App et al.			
	A7	5,792,771	Aug. 11, 1998	App et al.			
	A8	5,801,212	Sept. 1, 1998	Okamoto et al.			
	A9	5,855,866	Jan. 5, 1999	Thorpe et al.			
	A10	Re 36,256	Jul. 20, 1999	Spada et al.			
	A11	5,942,385	Aug. 24, 1999	Hirth			
	A12	5,981,569	Nov. 9, 1999	App et al.			
	A13	6,057,320	May 2, 2000	Spada et al.			
	A14	6,258,951	Jul. 10, 2001	Lohmann et al.			
	A15	6,303,600	Oct. 16, 2001	Cox et al.			
	A16	6,306,874	Oct. 23, 2001	Fraley et al.			
	A17	6,313,138	Nov. 6, 2001	Fraley et al.			
	A18	Re 37,650	Apr. 9, 2002	Myers et al.			
	A19	6,420,382	Jul. 16, 2002	Fraley et al.			
	A20	6,479,512	Nov. 12, 2002	Fraley et al.			
	A21	2002/0103230	Aug. 1, 2002	Renhowe et al.			

<i>Qel</i>	A22	2002/0107392	Aug. 8, 2002	Renhowe et al.			
	A23	2003/0028018	Feb. 6, 2003	Renhowe et al.			
	A24	6,605,617	Aug. 12, 2003	Renhowe et al.			
	A25	2003/0158224	Aug. 21, 2003	Renhowe et al.			
	A26	2003/0207883	Nov. 6, 2003	Renhowe et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
/	A27	2363459	Jun. 26, 1975	Germany			
/	A28	3634066	Apr. 21, 1988	Germany			
/	A29	19841985	Mar. 9, 2000	Germany			
/	A30	0 290 153	Nov. 9, 1998	Europe			
/	A31	0 509 717	Apr. 10, 1992	Europe			
/	A32	0 508 800	Oct. 14, 1992	Europe			
/	A33	0 747 771	Dec. 11, 1996	Europe			
/	A34	0 797 376	Sept. 24, 1997	Europe			
/	A35	1 086 705	Mar. 28, 2001	Europe			
/	A36	6-9952	Jan. 18, 1994	Japan			
/	A37	7-43896	Feb. 14, 1995	Japan			
/	A38	8-29973	Feb. 2, 1996	Japan			
/	A39	63-258903	Oct. 26, 1998	Japan			
/	A40	92/18483	Oct. 29, 1992	WO			
/	A41	92/20642	Nov. 26, 1992	WO			
/	A42	95/15758	Jun. 15, 1995	WO			
/	A43	95/18801	Jul. 13, 1995	WO			
/	A44	97/03069	Jan. 30, 1997	WO			
/	A45	97/34876	Sept. 25, 1997	WO			
/	A46	97/48694	Dec. 24, 1997	WO			
/	A47	98/13350	Apr. 2, 1998	WO			


QJ L

12-10-05

<i>Al</i>	A48	99/10349	Mar. 4, 1999	WO			
	A49	99/50263	Oct. 7, 1999	WO			
	A50	99/65897	Dec. 23, 1999	WO			
	A51	00/27379	May 18, 2000	WO			
	A52	01/02369	Jan. 11, 2001	WO			
	A53	01/28993	Apr. 26, 2001	WO			
	A54	01/29025	Apr. 26, 2001	WO			
	A55	01/52904	Jul. 26, 2001	WO			
	A56	01/55114	Aug. 2, 2001	WO			
	A57	01/62251	Aug. 30, 2001	WO			
	A58	01/62252	Aug. 30, 2001	WO			
	A59	02/18383	Mar. 7, 2002	WO			
	A60	02/22598	Mar. 21, 2002	WO			
	A61	02/32861	Apr. 25, 2002	WO			
	A62	03/004488	Jan. 16, 2003	WO			

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	A63		Aprelikova, O., et al., "FLT4, a novel Class III Receptor Tyrosine Kinase in chromosome 5q33-qter1," <i>Cancer Res.</i> , Vol. 52, pp. 746-748, February 1, 1992, published by The American Association for Cancer Research, Stanford University Libraries' High Wire Press, California, United States of America.
	A64		Beals, C. R. et al., "Nuclear Export of NF-ATc Enhanced by Glycogen Synthase Kinase-3," <i>Science</i> , Vol. 275, pp. 1930-1933, 28 March 1997.
	A65		Brownlees, J. et al., "Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3 β transgenes," <i>NeuroReport</i> , Vol. 8, No. 15, pp. 3251-3255, 20 October 1997; published by Rapid Science Publishers.
	A66		Chan, T. A. et al., "14-3-3 σ is required to prevent mitotic catastrophe after DNA damage," <i>Nature</i> , Vol. 401, pp. 616-620, 7 October 1999; published by Macmillan Magazines Ltd.
	A67		Chen, G. et al., "The Mood-Stabilizing Agent Valproate Inhibits the Activity of Glycogen Synthase Kinase-3," <i>J. Neurochem.</i> , Vol. 72, No. 3, 1999, pp. 1327-1330; published by Lippincott Williams & Wilkins, Inc., Philadelphia.
	A68		Chesi, M. et al., "Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma," <i>Blood</i> , Vol. 97, No. 3, pp. 729-736, 1 February 2001; published by The American Society of Hematology.
	A69		Connolly, D., et al., "Human Vascular Permeability Factor," <i>J. Biol. Chem.</i> , Vol. 264, pp. 20017-20024, 1989, published by The American Society For Biochemistry and Molecular Biology, Inc., Stanford University Libraries' High Wire Press, California, United States of America.
	A70		Connolly, D., et al., "Tumor Vascular Permeability Factor Stimulates Endothelial Cell Growth and Angiogenesis," <i>J. Clin. Invest.</i> , Vol. 84, pp. 1470-1478, November, 1989, published by The American Society for Clinical Investigation, Inc., Stanford University Libraries' High Wire Press, California, United States of America.
	A71		Cross, A. E. et al., "The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf," <i>Biochem J.</i> , Vol. 303, pp. 21-26, 1994; (printed in Great Britain).



<i>Al</i>	A72	DeVries, C., et al., "The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," <i>Science</i> , Vol. 255, pp. 989-991, February 21, 1992, published by The American Society for the Advancement of Science, Stanford University Libraries' High Wire Press, California, United States of America.
<i>1</i>	A73	Doukas, M. A. et al., "Effect of Lithium on Stem Cell and Stromal Cell Proliferation in vitro," <i>Exp. Hematol.</i> , Vol. 14, pp. 215-221, 1986; published by International Society for Experimental Hematology.
<i>1</i>	A74	Ferrara, N., et al., "The Biology of Vascular Endothelial Growth Factor," <i>Endocrinol. Rev.</i> , Vol. 18, No. 1, pp. 4-25, 1997, published by The Endocrine Society, Stanford University Libraries' High Wire Press, California, United States of America.
<i>1</i>	A75	Flückiger-Isler, R. E. et al., "Stimulation of rat liver glycogen synthesis by the adenosine kinase inhibitor 5-iodotubercidin," <i>Biochem. J.</i> , Vol. 292, pp. 85-91, 1993; (printed in Great Britain).
<i>1</i>	A76	Folkman, J., "Fighting Cancer by Attacking Its Blood Supply," <i>Scientific American</i> , Vol. 275, pp. 150-154, September, 1996, published by Scientific American, Inc., New York, New York, United States of America.
<i>1</i>	A77	Hammond, W. P. et al., "Lithium Therapy of Canine Cyclic Hematopoiesis," <i>Blood</i> , Vol. 55, No. 1, pp. 26-28, January, 1980.
<i>1</i>	A78	Heinrich, M. C. et al., "Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies," <i>J. Clin. Oncol.</i> , Vol. 20, No. 6, pp. 1692-1703, March 15, 2002.
<i>1</i>	A79	Hennequin, L. F., et al., "Design and Structure - Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors," <i>J. Med. Chem.</i> , Vol. 42, No. 26, pp. 5369-5389, 1999; published by American Chemical Society, Washington, D.C.
<i>1</i>	A80	Hirao, A. et al., "DNA Damage-Induced Activation of p53 by the Checkpoint Kinase Chk2," <i>Science</i> , Vol. 287, pp. 1824-1827, 10 March 2000.
<i>1</i>	A81	Klein, P. S. et al., "A molecular mechanism for the effect of lithium on development," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 93, pp. 8455-8459, August 1996.
<i>1</i>	A82	Lee, J. et al., "Positive Regulation of Wee1 by Chk1 and 14-3-3 Proteins," <i>Molecular Biology of the Cell</i> , Vol. 12, pp. 551-563, March 2001; published by The American Society for Cell Biology.
<i>1</i>	A83	Leung, D., et al., "Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen," <i>Science</i> , Vol. 246, pp. 1306-1309, December 8, 1989, published by The American Society for the Advancement of Science, Stanford University Libraries' High Wire Press, California, United States of America.
<i>1</i>	A84	Levis, M. et al., "A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo," <i>Blood</i> , Vol. 99, No. 11, pp. 3885-3891, 1 June 2002; published by the American Society of Hematology.
<i>1</i>	A85	Liu, Q. et al., "Chk1 is an essential kinase that is regulated by Atr and required for the G ₂ /M DNA damage checkpoint," <i>Genes & Development</i> , Vol. 14, 2000, pp. 1448-1459; published by Cold Springs Harbor Laboratory Press.
<i>1</i>	A86	Lopez-Girona, A. et al., "Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein," <i>Nature</i> , Vol. 397, pp. 172-175, 14 January 1999; published by Macmillan Magazines Ltd.
<i>1</i>	A87	Lovestone, S. et al., "Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells," <i>Current Biology</i> , Vol. 4, pp. 1077-1086, 1 December 1994; published by Elsevier Science Ltd.
<i>1</i>	A88	Lymboussaki, A., "Vascular endothelial growth factors and their receptors in embryos, adults, and in tumors," Academic Dissertation, University of Helsinki, Molecular/Cancer Biology Laboratory and Department of Pathology, Haartman Institute, 1999.
<i>1</i>	A89	Maguire, M.P., et al., "A New Series of PDGF Receptor Tyrosine Kinase Inhibitors: 3-Substituted Quinoline Derivatives," <i>J. Med. Chem.</i> , Vol. 37, No. 14, pp. 2129-2137, 1994; published by American Chemical Society, Washington, D.C.
<i>1</i>	A90	Massillon, D. et al., "Identification of the glycogenic compound 5-iodotubercidin as a general protein kinase inhibitor," <i>Biochem. J.</i> , Vol. 299, pp. 123-128, 1994; printed in Great Britain.
<i>1</i>	A91	Matei, S., et al., "Condensation of ethyl 2-benzimidazoleacetate with carbonyl compounds," <i>Rev. Chim.</i> , Vol. 33, No. 6, pp. 527-530, 1989, published by the Central Institute of Chemistry, Bucharest, Romania.
<i>1</i>	A92	Mustonen, T., et al., "Endothelial Receptor Tyrosine Kinases Involved in Angiogenesis," <i>J. Cell Biology</i> , Vol. 129, No. 4, pp. 895-898, May, 1995, published by The Rockefeller University Press, New York, New York, United States of America.
<i>1</i>	A93	Nonaka, S. et al., "Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 95, pp. 2642-2647, March 1998.
<i>1</i>	A94	Parker, L. L. et al., "Inactivation of the p34cdc2-Cyclin B Complex by the Human WEE1 Tyrosine Kinase," <i>Science</i> , Vol. 257, pp. 1955-1957, 25 September 1992.

<i>SL</i>	A95	Pei, J.-J. et al., "Distribution, Levels, and Activity of Glycogen Synthase Kinase-3 in the Alzheimer Disease Brain," <i>Journal of Neuropathology and Experimental Neurology</i> , Vol. 56, No. 1, pp. 70-78, January, 1997; published by the American Association of Neuropathologists.
	A96	Peng, C.-Y. et al., "Mitotic and G ₂ Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216," <i>Science</i> , Vol. 277, pp. 1501-1505, 5 September 1997.
	A97	Plouet, J., et al., "Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells," <i>EMBO J.</i> , Vol. 8, No. 12, pp. 3801-3806, 1989, published by IRL Press.
	A98	Quinn, T., et al., "Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 90, pp. 7533-7537, August, 1993.
	A99	Saito, Y. et al., "The mechanism by which epidermal growth factor inhibits glycogen synthase kinase 3 in A431 cells," <i>Biochem. J.</i> , Vol. 303, pp. 27-31, 1994; printed in Great Britain.
	A100	Sanchez, Y. et al., "Conservation of the Chk1 Checkpoint Pathway in Mammals: Linkage of DNA Damage to Cdk Regulation Through Cdc25," <i>Science</i> , Vol. 277, pp. 1497-1501, 5 September 1997.
	A101	Shibuya, M., et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (fit) closely related to the fms family," <i>Oncogene</i> , Vol. 5, pp. 519-524, 1990, published by Macmillan Press Ltd., Stockton Press Company, Great Britain.
	A102	Smolich, B.D. et al., "The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts," <i>Blood</i> , Vol. 97, No. 5, pp. 1413-1421, 1 March 2001; published by The American Society of Hematology.
	A103	Stambolic, V. et al., "Lithium inhibits glycogen synthase kinase-3 activity and mimics Wingless signaling in intact cells," <i>Current Biology</i> , Vol. 6, No. 12, pp. 1664-1668, 1996; published by Current Biology Ltd. ISSN 0960-9822.
	A104	Stover, D. R., "Recent advances in protein kinase inhibition: Current molecular scaffolds used for inhibitor synthesis," <i>Current Opinion in Drug Discovery & Development</i> , Vol. 2, No. 4, pp. 274-285, 1999; published by PharmaPress Ltd., London, United Kingdom.
	A105	Sun, T.-Q. et al., "PAR-1 is a Dishevelled-associated kinase and a positive regulator of Wnt signalling," <i>Nature Cell Biology</i> , Vol. 3, pp. 628-636, July 2001; published by Macmillan Magazines Ltd.
	A106	Takashima, A. et al., "tau protein kinase I is essential for amyloid β -protein-induced neurotoxicity," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 90, pp. 7789-7793, August 1993.
	A107	Takashima, A. et al., "Presenilin 1 associates with glycogen synthase kinase-3 β and its substrate tau," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 95, pp. 9637-9641, August 1998; published by The National Academy of Sciences.
	A108	Terman, B., et al., "Identification of a new endothelial cell growth factor receptor tyrosine kinase," <i>Oncogene</i> , Vol. 6, pp. 1677-1683, 1991, published by Macmillan Press Ltd., Stockton Press Company, Great Britain.
	A109	Thomas, M.D., R. J. et al., "Progress in Geriatrics: Excitatory Amino Acids in Health and Disease," <i>J. of the American Geriatrics Society</i> , Vol. 43, No. 11, November 1995; published by American Geriatrics Society.
	A110	Ukrainets, I., "Effective Synthesis of 3-(Benzimidazol-2-yl)-4-Hydroxy-2-Oxo-1,2-Dihydroquinolines," <i>Tet. Lett.</i> , Vol. 36, No. 42, pp. 7747-7748, 1995, published by Elsevier Science Ltd., Great Britain.
	A111	Ukrainets, I., et al., "2-Carbethoxymethyl-4H-3,1-Benzoxazin-4-One. 3. Condensation of o-Phenylenediamine," pp. 198-200, translated from <i>Khimiya Geterotsiklichesikh Soedinii</i> , No. 2, pp. 239-241, February, 1992, published by Plenum Publ. Corp., London, Great Britain.
	A112	Ukrainets, I., et al., "4-Hydroxy-2-Quinolones 7.* Synthesis and Biological Properties of 1-R-3-(Benzimidazolyl)-4-Hydroxy-2-Quinolones," pp. 92-94, translated from <i>Khimiya Geterotsiklichesikh Soedinii</i> , No. 1, pp. 105-108, January, 1993, published by Plenum Publ. Corp., London, Great Britain.
	A113	Ukrainets, I., et al., "4-Hydroxy-2-Quinolones. 16.* Condensation of N-R-Substituted Amides of 2-Carboxy-Malonanilic Acid With o-Phenylenediamine," pp. 941-944, translated from <i>Khimiya Geterotsiklichesikh Soedinii</i> , Vol. 8, pp. 1105-1108, August, 1993, published by Plenum Publ. Corp., London, Great Britain.
	A114	Ukrainets, I., et al., "4-Hydroxy-2-Quinolones. 32.* Synthesis and Antithyroid Activity of Thio Analogs of 1H-2-OXO-3-(2-Benzimidazolyl)-4-HydroxyQuinoline," <i>Chem. Heterocyclic Comp.</i> , Vol. 33, No. 5, pp. 600-604, 1997, published by Kluwer Academic Publishers, London, Great Britain.
	A115	Ullrich, A., et al., "Signal Transduction by Receptors with Tyrosine Kinase Activity," <i>Cell</i> , Vol. 61, pp. 203-212, April 20, 1990, published by Cell Press, Cambridge, Massachusetts, United States of America.

<i>Or</i>	A116	van der Geer, P., et al., "Receptor Protein-Tyrosine Kinases and Their Signal Transduction Pathways," <i>Annu. Rev. Cell Biol.</i> , Vol. 10, pp. 251-337, 1994, published by Annual Reviews, Inc., Palo Alto, California, United States of America.
<i>1</i>	A117	Vogelstein, B. et al., "Surfing the p53 network," <i>Nature</i> , Vol. 408, pp. 307-310, 16 November 2000; published by Macmillan Magazines Ltd.
<i>1</i>	A118	Welsh, G. I. et al., "Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B," <i>Biochem. J.</i> , Vol. 294, pp. 625-629, 1993; printed in Great Britain.
<i>1</i>	A119	Yamasaki, Y. et al., "Pioglitazone (AD-4833) Ameliorates Insulin Resistance in Patients with NIDDM," <i>Tohoku J. Exp. Med.</i> , Vol. 183, pp. 173-183, 1997.
<i>1</i>	A120	Zhao, H. et al., "ATR-Mediated Checkpoint Pathways Regulate Phosphorylation and Activation of Human Chk1," <i>Molecular and Cellular Biology</i> , Vol. 21, No. 13, pp. 4129-4139, July 2001; published by American Society for Microbiology.
<i>1</i>	A121	Zhang, Z. et al., "Destabilization of β -catenin by mutations in presenilin-1 potentiates neuronal apoptosis," <i>Nature</i> , Vol. 395, pp. 698-702, 15 October 1998; published by Macmillan Publishers Ltd.
<i>1</i>	A122	List of compounds purchased from various vendors (3 pages).
<i>1</i>	A123	CAS printout for 304876-79-7 Registry File, entry date into Registry File November 29, 2000.
<i>1</i>	A124	CAS printout for 300591-52-0 Registry File, entry date into Registry File October 31, 2000.
EXAMINER	<i>Ly Z</i>	DATE CONSIDERED <i>12/10/05</i>

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to Applicant.